Estimating and modeling the cure fraction in population-based cancer survival analysis
From MaRDI portal
Publication:5308153
DOI10.1093/biostatistics/kxl030zbMath1121.62096OpenAlexW2164665019WikidataQ29041007 ScholiaQ29041007MaRDI QIDQ5308153
Claire L. Weston, John R. Thompson, Paul W. Dickman, Paul C. Lambert
Publication date: 27 September 2007
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/kxl030
Applications of statistics to biology and medical sciences; meta analysis (62P10) Point estimation (62F10) Estimation in survival analysis and censored data (62N02)
Related Items (13)
Semiparametric estimation for accelerated failure time mixture cure model allowing non-curable competing risk ⋮ Discrete and continuous bivariate lifetime models in presence of cure rate: a comparative study under Bayesian approach ⋮ Waiting period from diagnosis for mortgage insurance issued to cancer survivors ⋮ Semiparametric estimation for proportional hazards mixture cure model allowing non-curable competing risk ⋮ Multi‐parameter regression survival modeling: An alternative to proportional hazards ⋮ A Bayesian approach to mixture cure models with spatial frailties for population-based cancer relative survival data ⋮ Modeling excess hazard with time‐to‐cure as a parameter ⋮ A survival model for lifetime with long-term survivors and unobserved heterogeneity ⋮ A new class of bivariate Sushila distributions in presence of right-censored and cure fraction ⋮ Block and Basu bivariate lifetime distribution in the presence of cure fraction ⋮ Approximate Bayesian inference for mixture cure models ⋮ A flexible cure rate model for spatially correlated survival data based on generalized extreme value distribution and Gaussian process priors ⋮ Estimating the turning point of the log-logistic hazard function in the presence of long-term survivors with an application for uterine cervical cancer data
This page was built for publication: Estimating and modeling the cure fraction in population-based cancer survival analysis
